Bristol Myers Squibb acquires MyoKardia for $13B

Bristol Myers Squibb on Oct. 5 inked a $13.1 billion deal to buy Brisbane, Calif.-based drugmaker MyoKardia, aiming to diversify its drug portfolio beyond oncology medicines. 

The New York City pharma giant will gain MyoKardia's mavacamten, an experimental heart drug that treats obstructive hypertrophic cardiomyopathy. The treatment has not been approved by the FDA yet.

"We are further strengthening our outstanding cardiovascular franchise through the addition of mavacamten, a promising medicine with the potential to address a significant unmet medical need in patients with cardiovascular disease," Bristol Myers Squibb CEO Giovanni Caforio, MD, said in a news release.

Under the deal, Bristol Myers Squibb will pay MyoKardia $225 a share in cash.

More articles on pharmacy:
Bipartisan bill aims to create subscription-style model for bigger antibiotic market
Drugmakers, PBMs must jointly face insulin price-fixing lawsuit, judge rules
Drugmakers testify on pricing strategy, PBM contracting in Congress

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.